Genetic predisposition, life-style habits and inflammatory bowel diseases (IBD)-related colitis are a main risk factor for colorectal cancer (CRC). 5-aminosalicylic acid (5-ASA, mesalazine) is a mainstay therapy in IBD and believed to reduce the risk for developing CRC. We aimed to determine the ability of 5-ASA enemas to inhibit the development of sporadic and colitis-related neoplasia in mice. FabplCre;Apc 15lox/+ mice, which spontaneously develop sporadic colorectal tumours, were treated at 5 weeks of age with 5-ASA or placebo enemas for 3 weeks and examined for colorectal tumourigenesis at 8 weeks of age. Colitis- 
Introduction
Inflammation and carcinogenesis are pathological consequences of injury and repair at a cellular and molecular level. Several studies suggest inflammation as a risk factor for the development of cancer, including CRC 1 . Individuals suffering from either of the two main chronic forms of IBD, ulcerative colitis (UC) and Crohn's disease (CD), are at increased risk of developing CRC 2, 3 . 5-ASA is a non-steroid anti-inflammatory drug, widely used in the maintenance of remission and treatment of mild inflammatory exacerbations in IBD. Most epidemiological studies have shown that the chronic use of 5-ASA in IBD has chemopreventive effects on the development of CRC, although some studies failed to show this, as described in a recent meta-analysis by Velayos et al. 4 . To study prospectively whether 5-ASA has chemopreventive actions in patients is hardly feasible, due to duration of the study, high patient numbers needed, and ethical considerations. Therefore, for this kind of research animal models are used which mimic the human disease, although most models lack similarities.
The Apc Min/+ mouse model carries a germline mutation in one allele of the adenomatous polyposis coli (Apc) tumour suppressor gene. Apc Min/+ mice develop multiple intestinal neoplasia (min), mainly in the small intestine, due to loss of function of the intact Apc + allele 5 . Apc is a crucial negative regulator of the canonical Wnt pathway, forming a complex with axins and glycogen synthase 3β kinase (GSK3β), targeting β-catenin for degradation. Loss of functional Apc prevents formation of the complex, resulting in accumulation of β-catenin. Upon translocation to the nucleus and association with the TCF-4 transcription factor, β-catenin induces transcriptional activation of many genes involved in cell adhesion, migration and proliferation 6 . The Apc Min/+ mouse model mimics the familial adenomatous polyposis (FAP) syndrome in humans, an inherited form of CRC, caused by a germline APC mutation and characterized by development of 100s-1000s adenomas in the large intestine. Most CRCs, however, are sporadic but they share early APC mutations in 80% of the cases.
Reports on the effects of 5-ASA on the development of intestinal polyps in Apc
Min/+ mice have been conflicting. McGregor et al. 7 showed that 5-ASA reduced the number of polyps, whereas Ritland et al. 8 found no reduction in polyp numbers. The Apc Min/+ mouse model is limited for studying the chemopreventive effect of 5-ASA on the development of CRC, because these mice develop only a small fraction of lesions in the colon compared to the small intestine, and intestinal tumourigenesis is most likely already initiated in the first 2 weeks of life in these mice.
Recently, we generated a novel tissue-specific, sporadic CRC mouse model, A widely used and thoroughly described colitis model is the dextran sodium sulphate (DSS) model. DSS dissolved in the drinking water of rodents, induces intestinal inflammation, including crypt damage and crypt loss. When DSS is applied in a low concentration (2% w/v) for a few days, followed by a period of normal drinking water, the inflammatory period is followed by a healing and repair period, resembling exacerbation and remission stages in human UC 9, 10 . DSS-induced colitis in the Apc Min/+ mouse model was shown to accelerate the development of colorectal tumours, and to be useful as a colitisassociated intestinal cancer model 11, 12 .
In the present study we determined the effects of local 5-ASA treatment on the development of colorectal tumours in: 1) FabplCre;Apc 15lox/+ mice, which develop distally located tumours, to mimic human sporadic CRC development, and 2) FabplCre;Apc 15lox/+ mice exposed to DSS, to study colitis-associated development of neoplasia. 5-ASA was found to effectively reduce the development of colitis-associated tumours, whereas it was ineffective in inhibiting sporadic tumour development.
Material&Methods

Mice
All animal studies were approved by the ethical committee for animal studies of the 
Colitis induction
Colonic inflammation was induced in 5 weeks old mice, with a median body weight of 17.5 gram (range 13.0-22.0), by administration of 2% (w/v) DSS (MP Biomedicals, Aurora, Ohio, USA; MW=36,000-50,000) in tap water to the mice ad libitum. The solution was refreshed every other day, and the consumption was monitored daily by weighing the drinking bottle. In order to induce inflammation followed by a recovery period, the 2% DSS solution was given for 5 days followed by 16 days of tap water ( Figure 1A ). Mice were sacrificed at the end of the experiment at 8 weeks of age, or before the end of the experiment if they exhibited >20% weight loss, rectal bleeding, anaemia, and lethargy. These latter mice were excluded from the results of the neoplasia scoring.
5-ASA medication
Salofalk 4gr Figure 1A ). In the second experiment the FabplCre;Apc 15lox/+ mice were treated simultaneously with DSS and 5-ASA or placebo medication during the DSS-induced colitis (DSS+5-ASA and DSS+Placebo groups), or with 5-ASA only in the subsequent two week recovery period (5-ASA-post-DSS group, experiment 2, Figure 1B) .
Assessment of colitis
The presence of blood in faeces, stool consistency, and general appearance were recorded daily for each animal. Together, these factors constitute the disease activity index (DAI, range 0-6, Table 1 ), as adapted from Cooper et al. 9 . The daily recorded body weight was not included in the DAI. 
Histopathology
The large intestine (from caecum to anus) of sacrificed mice was isolated and the length was measured in a relaxed position without stretching. The large intestine was opened longitudinally, cleaned in phosphate-buffered saline (PBS), spread onto filter paper (luminal side up), fixed in buffered 4% formalin (pH 7.2) for 24 hours at RT, and stored in 70% 
Immunohistochemistry
Paraffin sections were deparaffinized, endogenous peroxidase activity was blocked in 
Statistical analysis
Statistical analysis of the changes in bodyweight, DAI, MAI, length of the large intestine, the number of neoplastic lesions and the (immuno)histology scores were performed using the Student t-test. Differences were considered significant when P≤0.05.
Results
Increased disease activity index and loss of body weight due to DSS
The typical colitis symptoms, recorded as the DAI, increased dramatically in FabplCre;Apc 15lox/+ mice during and shortly after the five-day-DSS period in both DSS/5-ASA and DSS/Placebo groups ( Figure 2A ). In addition, both DSS-treated groups displayed a gradual loss of body weight at the end and shortly after the DSS period in contrast to the two non-DSS-treated groups ( Figure 2B ). The DSS-treated animals recovered from this severe colitis during the next two weeks, as indicated by a decrease in DAI and gain of body weight.
In general, 5-ASA treatment by enema tended to a faster/better recovery of the DSS-treated mice (Figure 2A/B) . This difference could not be attributed to a difference in consumption of DSS-supplemented drinking water ( Figure 2C ).
DSS-induced colitis accelerates large intestinal tumourigenesis
Due to the DSS-induced colitis, the length of the large intestine of the DSS/Placebo group was significantly decreased compared to that of non-treated mice on average from 9.3 to 7.5 cm (P<0.0001, Figure 3A 
5-ASA suppresses colitis-accelerated large intestinal tumourigenesis
5-ASA treatment tended to increase the length of the large intestine of FabplCre;Apc 15lox/+ mice treated with DSS (on average from 7.5 cm to 7.9 cm, P=0.17, Figure 3B ). More importantly, however, 5-ASA treatment significantly reduced the average Figure 3C ). In contrast, 5-ASA treatment was unable to reduce the average number of sporadic tumours in the large intestine (5.2 and 4.8 tumours in the 5-ASA group and Placebo group, respectively, P=0.93, Figure 3C ).
5-ASA exerts tumour-inhibiting effect during recovery period
To determine whether 5-ASA exerted its preventive effect due to anti-inflammatory actions on the DSS-induced colitis or due to effects during the recovery period, mice were treated with 5-ASA or placebo enemas during the DSS administration period and 2 days thereafter (DSS+5-ASA group and DSS+Placebo group), and with 5-ASA enemas only during the two weeks of subsequent colitis recovery (5-ASA-post-DSS group, experiment 2, Figure 1B ). The DAI and the body weight changes of these DSS-treated mice showed similar curves as those of the corresponding DSS-treated animals of experiment 1 (not shown). 
5-ASA exerts tumour-inhibiting effect in the distal large intestine
We examined the tumour-inhibiting effect of the 5-ASA treatment in more detail. 
5-ASA-treated area. Bars (mean + SEM) indicate total tumour numbers (black), tumours <2 mm (grey), and tumours ≥2 mm (white) (B,C). Significant P-values ≤0.05 are shown in bold (B,C).
number and size of tumours in the 5-ASA-treated area (P=0.14-0.21, Figure 4B ), leaving the more proximal large intestine unaffected ( Figure 4C ).
Non-treated DSS/Placebo
DSS/5-ASA Immunohistochemistry showed nuclear accumulation of β-catenin in all tumours analyzed (illustrated in Figure 7A ,D,G), indicating that the Wnt pathway was upregulated due to functional loss of the Apc + allele in all tumours. We did not detect any obvious differences in intensity or localization, i.e., nuclear versus membranous/cytoplasmic, of β-catenin between the different groups.
The extent of proliferation, as determined by immunohistochemistry for Ki67, of both neoplastic cells and normal intestinal epithelial cells was similar for the non-treated, neoplastic cells (all groups P<0.003) than that of normal epithelial cells ( Figure 7B,E,H,K,J) . 
Immunohistochemical analysis of neoplastic lesions in the distal large intestine from non-treated (A-C), DSS/Placebo-treated (D-F), and DSS/5-ASA-treated (G-I) FabplCre;Apc 15lox/+ mice and normal crypts from non-treated mice (J,K,L) for β-catenin (A,D,G,J), for Ki67 to determine the extent of proliferation (B,E,H,K), and for active caspase-3 to determine the extent of apoptosis (C,F,G,L). Original magnification 400 x. Fullcolour image on page 188.
Quantification illustrated that 5-ASA tended to reduce the proliferation of neoplastic cells in the DSS/5-ASA group when compared with the DSS/Placebo group (on average from 55.6% to 52.7%, P=0.09, Figure 8 ), but 5-ASA did not reduce proliferation of normal epithelial cells in these two groups (P=0.47, Figure 8 ). The tendency to reduce proliferation of neoplastic cells by 5-ASA was not found in the groups without DSS treatment (P=0.73, Figure 8 ). Overall, proliferation of neoplastic and normal epithelial cells in the DSS-treated groups was very similar to that in the non-DSS-treated groups. Finally, we investigated the extent of apoptosis by immunohistochemical detection of active caspase-3, an apoptotic protease. Apoptotic cells were mainly found at the top of normal crypts ( Figure 7L ) and incidentally in the lamina propria, whereas a heterogeneous distribution of apoptotic cells was seen in tumour tissue ( Figure 7C,F,I ). 21 .
In contrast to several in vitro and in vivo studies on the effect of 5-ASA on CRC cells [24] [25] [26] [27] , we found a somewhat higher but no significant increase of apoptosis in the intestinal tissues due to 5-ASA administration. We used active caspase-3 immunohistochemistry to investigate apoptosis, which worked well but hampered the exact identification and counting of the percentage of apoptotic cells, because of additional staining of other (non-epithelial) apoptotic cells and cellular debris in the crypts and of extruded cells. Detection of the caspase-degraded product of cytokeratin 18 by M30 immunohistochemistry, widely used on human tissues and easy to quantify epithelial apoptosis, unfortunately did not work in our hands (not shown) since it is probably not specific for mouse. 5-ASA might also induce cell death via non-caspase mechanisms (Chapter 5).
5-ASA was not able to prevent the development of sporadic tumours in the FabplCre;Apc 15lox/+ mice. Apparently 5-ASA can not prevent colorectal tumourigenesis which is solely driven by the Apc mutation, and thereby mimicking sporadic CRC development. Moreover, 5-ASA did not affect the proliferation of neoplastic cells in these sporadic CRCs, in line with the absence of a preventive effect. These observations correspond to the data from Ritland et al. 8 , describing no effect on the development of adenomas in the Apc Min/+ mouse model. The only study performed in humans, addressing whether 5-ASA prevents sporadic CRC, examined the recurrence rate of sporadic colorectal adenomas in patients who underwent polypectomywas not able to reduce the adenoma recurrence rate, and was therefore unlikely to prevent sporadic CRC, in line with the results presented here.
As far as we know this is the first report that used a mouse model to study the effect of 5-ASA enema treatment on the development of both sporadic and colitis-associated colorectal neoplasia. One could argue that the used FabplCre;Apc 15lox/+ mouse model in combination with DSS-induced colitis is a too robust model, in which colorectal tumourigenesis is so strongly accelerated, that it does not really mimic colitis-associated CRC in human IBD patients, which takes decades to develop. One could also argue that due to the robustness of the model a small chemopreventive effect is unlikely to be found. The fact that we did find an effect of 5-ASA shows the contrary: the FabplCre;Apc 15lox/+ mouse in combination with DSS is a very useful model to investigate the chemopreventive effects of certain agents on colitis-associated carcinogenesis rather quickly and can also be used to study prevention of sporadic CRC.
In conclusion, in the present study we observed that chronically administered 5-ASA inhibited colitis-associated neoplasia in a mouse model, whereas it did not prevent the development of sporadic tumours, very much in line with the available data from human studies.
